Literature DB >> 29745096

Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer.

Antonios-Apostolos Tentes1, Nicolaos Pallas, Christina Karamveri, Dimitrios Kyziridis, Christos Hristakis.   

Abstract

PURPOSE: Peritoneal carcinomatosis of pancreatic cancer is generally considered for palliative treatment. The purpose of this study was to report the outcome of cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in patients with pancreatic cancer and peritoneal carcinomatosis.
METHODS: Patients with documented resectable peritoneal carcinomatosis of pancreatic cancer underwent cytoreductive surgery in combination with HIPEC from 2008-2016 by the same surgical team.
RESULTS: Six patients underwent 8 cytoreductions. Complete or near-complete cytoreduction was possible in 7 cases, and palliative surgery in one case. Gemcitabine was used in 5 cases during HIPEC, and cisplatin+mitomycin-C in 2 others. All patients received adjuvant chemotherapy with gemcitabine. Four patients survived without evidence of recurrence for more than 12 months.
CONCLUSIONS: Cytoreductive surgery with HIPEC may be considered a treatment option in highly selected patients with pancreatic cancer and peritoneal carcinomatosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29745096

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  12 in total

1.  The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.

Authors:  Alexandre Brind'Amour; Mitchell Webb; Marina Parapini; Lucas Sidéris; Maja Segedi; Stephen W Chung; Stéphanie Chartier-Plante; Pierre Dubé; Charles H Scudamore; Peter T W Kim
Journal:  Clin Exp Metastasis       Date:  2021-01-24       Impact factor: 5.150

2.  Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment.

Authors:  Vaidotas Cesna; Arturas Sukovas; Aldona Jasukaitiene; Giedre Silkuniene; Saulius Paskauskas; Zilvinas Dambrauskas; Antanas Gulbinas
Journal:  Oncol Lett       Date:  2019-06-18       Impact factor: 2.967

3.  Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study.

Authors:  Travis E Grotz; Jennifer A Yonkus; Cornelius A Thiels; Susanne G Warner; Robert R McWilliams; Amit Mahipal; Tanios S Bekaii-Saab; Sean P Cleary; Michael L Kendrick; Mark J Truty
Journal:  Ann Surg Oncol       Date:  2022-08-16       Impact factor: 4.339

4.  Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41.

Authors:  David Padilla-Valverde; Esther García-Santos; Susana Sanchez; Carmen Manzanares; Marta Rodriguez; Lucia González; Alfonso Ambrós; Juana M Cano; Leticia Serrano; Raquel Bodoque; Teresa Vergara; Jesus Martin
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection.

Authors:  Antonios-Apostolos K Tentes
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review.

Authors:  Andreas Larentzakis; Evangelos Anagnostou; Konstantinos Georgiou; Gavriella-Zoi Vrakopoulou; Constantinos G Zografos; Georgios C Zografos; Konstantinos G Toutouzas
Journal:  Oncol Lett       Date:  2021-02-03       Impact factor: 2.967

7.  Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report.

Authors:  Richard A Hoefer; Chukwuemeka Obiora; Basem Azab; Elizabeth A Harden; John F Kessler
Journal:  Int J Surg Case Rep       Date:  2021-05-29

8.  Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis.

Authors:  Tao Cheng; Zhiheng Zhang; Hua Shen; Ziying Jian; Junsheng Li; Yujun Chen; Yi Shen; Xinyi Dai
Journal:  J Nanobiotechnology       Date:  2020-09-05       Impact factor: 10.435

Review 9.  Molecular mediators of peritoneal metastasis in pancreatic cancer.

Authors:  Leela Rani Avula; Brendan Hagerty; Christine Alewine
Journal:  Cancer Metastasis Rev       Date:  2020-08-11       Impact factor: 9.264

10.  A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma.

Authors:  Can Yurttas; Philipp Horvath; Imma Fischer; Christoph Meisner; Silvio Nadalin; Ingmar Königsrainer; Alfred Königsrainer; Stefan Beckert; Markus W Löffler
Journal:  Ann Surg Oncol       Date:  2021-06-15       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.